rEECur
An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Bone Cancers (Ewing Sarcoma/Osteosarcoma), Soft Tissue Sarcomas
This trial aims to discover which is the most successful treatment for a child or young person who has relapsed with Ewing Sarcoma. Currently, it is not known which chemotherapy drug combination provides the most successful treatment for a child or young person who has relapsed. This trial, the first of its kind world-wide, aims to find out which course of treatment is the most effective and with the least side effects.
The trial allows for three different chemotherapy drug combinations to be randomly given to each child or young person. These drug combinations are called ‘treatment arms’. There are some exclusions based on a number of factors including what treatment the child or young person has already received. To be included the child or young person needs to be eligible for at least 2 treatment arms.
Disease Stage: Recurrent or primary refractory
Patient Age Range: >4 years to <50 years
Sample Size: 600
Trial Sponsors:
- International: University of Birmingham
- National: ANZCHOG in partnership with ANZSA
Read more at the Clinical Trial Registry
Sites
Children’s Hospital at Westmead
John Hunter Children’s Hospital
Monash Children’s Hospital, Melbourne
Perth Children’s Hospital
Queensland Children’s Hospital
Sydney Children’s Hospital
Women’s and Children’s Hospital, Adelaide
Christchurch Hospital, NZ
Starship Children’s Hospital, Auckland, NZ
Peter MacCallum Cancer Centre, Melbourne
Princess Alexandra, Queensland
Prince of Wales
Royal Adelaide
Sir Charles Gairdner Hospital
Chris O’Brien Lifehouse